FDA approves  asciminib for Philadelphia chromosome-positive chronic myeloid leukemia 

On October 29, 2021, the Food and Drug Administration granted accelerated approval to asciminib (Scemblix, Novartis AG) for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs).

Source: FDA Center for Drug Evaluation and Research - What's New - October 29, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news